Overview

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Status:
Terminated

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies the side effects and how well omacetaxine mepesuccinate, cytarabine, and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia. Omacetaxine mepesuccinate, cytarabine, and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborators:

National Cancer Institute (NCI)
Teva Pharmaceutical Industries, Ltd.

Treatments:

Azacitidine
Cytarabine
Decitabine
Harringtonines
Homoharringtonine